Buy TARO-DOXORUBICIN LIPOSOMAL 2 MG DOXORUBICIN HYDROCHLORIDE

Taro-Doxorubicin Liposomal 2 mg is a liposomal formulation of doxorubicin hydrochloride, used for targeted chemotherapy. This intravenous suspension is designed for specific cancer treatments, offering a controlled release mechanism.

Strength

2 MG

Manufacturer / TM Owner

TARO PHARMACEUTICALS INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Taro-Doxorubicin Liposomal 2 mg is primarily used in the treatment of certain types of cancer. The liposomal formulation helps to deliver the active ingredient, doxorubicin hydrochloride, directly to the tumor site, potentially reducing side effects associated with traditional chemotherapy. This medication is often prescribed for conditions where targeted therapy is beneficial.

Side Effects

Common effects of Taro-Doxorubicin Liposomal 2 mg may include fatigue, nausea, and hair loss. Some patients may experience more severe reactions, such as changes in blood cell counts or heart-related issues. It is important to monitor for any unusual symptoms and consult a healthcare provider if concerns arise.

Precautions & Warnings

Taro-Doxorubicin Liposomal 2 mg should be handled with care, as it is intended for intravenous use only. Proper administration by a healthcare professional is crucial to minimize risks. Patients should be aware of potential allergic reactions and inform their healthcare provider of any pre-existing conditions.

Avoid Interactions

Taro-Doxorubicin Liposomal 2 mg may interact with other medications, including those that affect the heart or immune system. Alcohol and certain supplements may also influence its effectiveness. Always inform your healthcare provider about all medications and supplements you are taking.

References

Frequently Asked Questions

Taro-Doxorubicin Liposomal 2 mg is used in the treatment of certain types of cancer, providing targeted chemotherapy.

This medication is administered intravenously by a healthcare professional.

Common side effects may include fatigue, nausea, and hair loss. Severe reactions can occur, so monitoring is important.

It may interact with other medications, so it is important to inform your healthcare provider about all medications you are taking.

Proper administration by a healthcare professional is crucial, and patients should be aware of potential allergic reactions.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.